Antimicrobial compounds and methods of making and using the same

1. A compound having the formula:

wherein Z is selected from the group consisting of NR 4 , NR 4 CO, or NR 4 CONR 4 ,

C—B-A-, D-E-F, and -G-H-J are chemical moieties, wherein

D-E-F is hydrogen or halogen;

A and G are independently selected from the group consisting of:

(a) a single bond, (b) —(C 1-8 alkyl)-, (c) —(C 2-8 alkenyl)-, (d) —(C 2-8 alkynyl)-, wherein

i) 0-4 carbon atoms in any of (b)-(d) immediately above optionally is replaced by a moiety selected from the group consisting of —O—, —S(O) p —, —NR 6 —, —(C═O)—, —S(O) p NR 6 —, —NR 6 S(O) p —, and —NR 6 S(O) p NR 6 —,

ii) any of (b)-(d) immediately above optionally is substituted with one or more R 5 groups, and

iii) any of (b)-(d) immediately above optionally is substituted with —(C 1-8 alkyl)-R 5 groups;

(e) —O—, (f) —NR 6 —, (g) —S(O) p —, (h) —C(O)—, (i) —C(O)O—, (j) —OC(O)—, k) —OC(O)O—, (l) —C(O)NR 6 —, (m) —NR 6 CO—, (n) —NR 6 C(O)NR 6 —, (o) —C(═NR 6 )—, (p) —C(═NR 6 )O—, (q) —OC(═NR 6 )—, (r) —C(═NR 6 )NR 6 —, (s) —NR 6 C(═NR 6 )—, (t) —C(═S)—, (u) —C(═S)NR 6 —, (V) —NR 6 C(═S)—, (w) —C(O)S—, (x) —SC(O)—, (y) —OC(═S)—, (z) —C(═S)O—, (aa) —NR 6 (CNR 6 )NR 6 —, (bb) —CR 6 R 6 C(O)—, (cc) —C(O)NR 6 (CR 6 R 6 ) t —, (dd) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(ee) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and

(ff) —(CR 6 R 6 ) t —,

wherein (dd) or (ee) is optionally substituted with one or more R 5 groups;

B and H are independently selected from the group consisting of:

(a) a single bond,

(b) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(c) a 3-14 member saturated, unsaturated, or aromatic carbocycle,

wherein (b) or (c) is optionally substituted with one or more R 5 groups;

(d) —(C 1-8 alkyl)-, (e) —(C 2-8 alkenyl)-, (f) —(C 2-8 alkynyl)-, wherein

i) 0-4 carbon atoms in any of (d)-(f) immediately above optionally is replaced by a moiety selected from the group consisting of —O—, —S(O) p —, —NR 6 —, —(C═O)—, —C(═NR 6 )—, —S(O) p NR 6 —, —NR 6 S(O) p —, and —NR 6 S(O) p NR 6 —,

ii) any of (d)-(f) immediately above optionally is substituted with one or more R 5 groups, and

iii) any of (d)-(f) immediately above optionally is substituted with —(C 1-8 alkyl)-R 5 groups;

and (g) —(CR 6 R 6 ) t —,

C and J are independently selected from the group consisting of:

(a) hydrogen, (c) F, (d) Cl, (e) Br, (f) I, (g) —CF 3 , (h) —CN, (i) —N 3 (j) —NO 2 , (k) —NR 6 (CR 6 R 6 ) t R 8 , (l) —OR 8 , (m) —S(O) p (CR 6 R 6 ) t R 8 , (n) —C(O)(CR 6 R 6 ) t R 8 , (o) —OC(O)(CR 6 R 6 ) t R 8 , (p) —SC(O)(CR 6 R 6 ) t R 8 , (q) —C(O)O(CR 6 R 6 ) t R 8 , (r) —NR 6 C(O)(CR 6 R 6 ) t R 8 , (s) —C(O)NR 6 (CR 6 R 6 ) t R 8 , (t) —C(═NR 6 )(CR 6 R 6 ) t R 8 , (u) —C(═NNR 6 R 6 )(CR 6 R 6 ) t R 8 , (v) —C(═NNR 6 C(O)R 6 )(CR 6 R 6 ) t R 8 , (w) —C(═NOR 8 )(CR 6 R 6 ) t R 8 , (x) —NR 6 C(O)O(CR 6 R 6 ) t R 8 , (y) —OC(O)NR 6 (CR 6 R 6 ) t R 8 , (z) —NR 6 C(O)NR 6 (CR 6 R 6 ) t R 8 , (aa) —NR 6 S(O) p (CR 6 R 6 ) t R 8 , (bb) —S(O) p NR 6 (CR 6 R 6 ) t R 8 , (cc) —NR 6 S(O) p NR 6 (CR 6 R 6 ) t R 8 , (dd) —NR 6 R 8 , (ee) —NR 6 (CR 6 R 6 )R 8 , (ff) —OH, (gg) —NR 8 R 8 , (hh) —OCH 3 , (ii) —S(O) p R 8 , (jj) —NC(O)R 8 , (kk) —NR 6 C(NR 6 )NR 6 R 8 , (ll) a C 1-8 alkyl group, (mm) a C 2-8 alkenyl group, (nn) a C 2-8 alkynyl group, (oo) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (pp) a 3-14 member saturated, unsaturated, or aromatic carbocycle, (qq) —(CR 6 R 6 ) t NR 6 (CR 6 R 6 ) t R 8 , (rr) —N[(CR 6 R 6 ) t R 8 ][C═O(CR 6 R 6 ) t R 8 ], (ss) —(CR 6 R 6 ) t N[(CR 6 R 6 ) t R 8 ][(CR 6 R 6 ) t R 8 ], (tt) —(CR 6 R 6 ) t NR 6 (C═O)(CR 6 R 6 ) t R 8 , (uu) -haloalkyl, (vv) —C(O)(CR 6 )[(CR 6 R 6 ) t R 8 ]R 8 , (ww) —(CR 6 R 6 ) t C(O)NR 8 R 8 , (xx) —(CR 6 R 6 ) t C(O)O(CR 6 R 6 ) t R 8 , (yy) —NR 6 C(O)CR 8 R 8 R 8 , (zz) —N[(CR 6 R 6 ) t R 8 ]C(O)R 8 , and (aaa) —S(O) p NR 8 R 8 ;

wherein (ll) through (pp) is optionally substituted with one or more R 7 groups;

R 5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NR 6 R 6 , (k) —OR 8 , (l) —NR 6 (CNR 6 )NR 6 R 6 , (m) —C 1-8 alkyl, (n) —C 1-8 alkenyl, (o) —C 1-8 alkynyl, (p) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r) -haloalkyl, (s) —SR 6 , (t) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u) -3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R 5 groups are taken together to form a carbocycle,

wherein (m) through (r) and (t) through (u) is optionally substituted with one or more R 8 ;

R 6 is selected from (a) hydrogen, (b) —C 1-8 alkyl or alternatively two R 6 groups are taken together to form a carbocycle, (c) -haloalkyl, (d) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e) -3-14 member saturated, unsaturated, or aromatic carbocycle;

wherein (b) through (e) is optionally substituted with one or more R 8 ;

R 7 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NR 6 R 6 , (k) —OR 6 , (l) —NR 6 (CNR 6 )NR 6 R 6 , (m) —C 1-8 alkyl, (n) —C 1-8 alkenyl, (o) —C 1-8 alkynyl, (p) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r) -haloalkyl, (s) —NR 6 R 8 , (t) —OR 8 , (u) —(CR 6 R 6 ) t NR 6 R 8 , (v) —CR 6 R 8 R 8 , (w) —SR 6 , (x) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (y) -3-14 member saturated, unsaturated, or aromatic carbocycle, (z) —(CR 6 R 6 ) t C(O)NR 8 R 8 , (aa) —S(O) p R 8 , (bb) —NR 6 C(O)NR 6 R 6 , (cc) —NR 6 C(O)R 6 , and (dd) —C(═NR 6 )NR 6 R 6 ;

wherein (m) through (q) and (x) through (y) are optionally substituted with one or more R 9 ;

R 8 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NR 6 R 9 , (k) —OR 9 , (l) —NR 6 (CNR 6 )NR 6 R 6 , (m) —C 1-8 alkyl, (n) —C 1-8 alkenyl, (o) —C 1-8 alkynyl, (p) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (s) -3-14 member saturated, unsaturated, or aromatic carbocycle, (t) -haloalkyl, (u) —C(O)(CR 6 R 6 ) t R 9 , (v) —SR 6 , (w) —OC(O)(CR 6 R 6 ) t R 9 , (x) —NR 6 C(O)NR 6 R 9 , (y) —NR 6 C(O)R 9 , (z) —NR 6 (CNR 9 )(NR 6 R 6 ), (aa) —ONR 6 (CNR 6 )NR 6 R 6 , (bb) —C(═NR 9 )NR 6 R 6 , (cc) —S(O) p R 9 , (dd) —(CR 6 R 6 ) t C(O)NR 6 R 9 , (ee) —(CR 6 R 6 ) t OR 9 , and (ff) —(CR 6 R 6 ) t NR 6 R 9 ;

wherein (m) through (s) is optionally substituted with one or more R 9 ;

R 9 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NR 6 R 10 , (k) —OR 6 , (l) —NR 6 (CNR 6 )NR 6 R 6 , (m) —C(O)(CR 6 R 6 ) t NR 6 R 6 , (n) —C 1-8 alkyl, (o) —C 1-8 alkenyl, (p) —C 1-8 alkynyl, (q) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r) -3-14 member saturated, unsaturated, or aromatic carbocycle, (s) -haloalkyl, (t) —(CR 6 R 6 ) t OR 6 , (u) —O(CR 6 R 6 ) t NR 6 R 10 , (v) —C(O)R 6 , (w) —SR 6 , (x) —C(O)OR 10 , (y) —S(O) p R 6 , (z) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) —O(CR 6 R 6 ) t OR 6 , (cc) —C(═NR 6 )NR 6 R 6 , (dd) —ONR 6 R 6 , (ee) —NR 6 C(O)NR 6 R 6 , (ff) —O(CR 6 R 6 ) t OR 6 ; (gg) —NR 6 C(O)R 6 , and (hh) —(CR 6 R 6 ) t NR 6 R 10 ;

wherein (n) through (r) and (z) through (aa) is optionally substituted with one or more R 10 ;

R 10 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NR 6 R 6 , (k) —OR 6 , (l) —NR 6 (CNR 6 )NR 6 R 6 , (m) —C(O)(CR 6 R 6 )NR 6 R 6 , (n) —C 1-8 alkyl, (o) —C 1-8 alkenyl, (p) —C 1-8 alkynyl, (q) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r) -3-14 member saturated, unsaturated, or aromatic carbocycle, (s) -haloalkyl, (t) —(CR 6 R 6 ) t OR 6 , (u) —O(CR 6 R 6 ) t NR 6 R 6 , (v) —C(O)R 6 , (w) —SR 6 , (x) —C(O)OR 6 , (y) —S(O) p R 6 , (z) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (bb) —O(CR 6 R 6 ) t OR 6 , (cc) —C(═NR 6 )NR 6 R 6 , (dd) —ONR 6 R 6 , (ee) —NR 6 C(O)NR 6 R 6 , (ff) —O(CR 6 R 6 ) t OR 6 , (gg) —NR 6 C(O)R 6 , and (hh) —(CR 6 R 6 ) t NR 6 R 6 ;

p is 0, 1, or 2, and

t is 0, 1, 2, or 3,

or a pharmaceutically acceptable salt or tautomer thereof.

2. The compound according to claim 1 , wherein Z is —NR 4 CONR 4 —; or a pharmaceutically acceptable salt or tautomer thereof.

3. The compound according to claim 2 ,

wherein Z is —NHCONH—; or a pharmaceutically acceptable salt or tautomer thereof.

4. The compound according claim 3 , wherein

A is selected from

(a) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(b) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and

(c) a single bond,

wherein (a) or (b) is optionally substituted with one or more R 5 groups;

B is selected from (a) —(C 1-8 alkyl)-, (b) —(C 2-8 alkenyl)-, (c) —(C 2-8 alkynyl)-, (d) a single bond, wherein

i) 0-4 carbon atoms in any of (a)-(c) immediately above optionally is replaced by a moiety selected from the group consisting of —O—, —S(O) p —, —NR 6 —, —(C═O)—, —C(═NR 6 )—, —S(O) p NR 6 —, and —NR 6 S(O) p NR 6 —,

ii) any of (a)-(c) immediately above optionally is substituted with one or more R 5 groups, and

iii) any of (a)-(c) immediately above optionally is substituted with —(C 1 -C 8 alkyl)-R 5 groups, and

C is selected from (a) NH 2 , (b) —NHC(═NH)NH 2 and (c) hydrogen;

or a pharmaceutically acceptable salt or tautomer thereof.

5. The compound according to claim 4 , wherein

A is selected from azepanyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridinyl, cyclohexenyl, cyclohexadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, and piperidenyl;

wherein any of A immediately above optionally is substituted with one or more R 5 groups;

alternatively, A is a single bond;

B is selected from (a) —(C 1-8 alkyl)-, wherein

i) 0-4 carbon atoms in (a) immediately above optionally is replaced by a moiety selected from the group consisting of —O—, —S(O) p —, —NR 6 —, —(C═O)—, —S(O) p NR 6 —, and —NR 6 S(O) p NR 6 —,

ii) (a) immediately above optionally is substituted with one or more R 5 groups, and

iii) (a) immediately above optionally is substituted with —(C 1-8 alkyl)-R 5 groups; and

alternatively, B is a single bond;

C is selected from (a) NH 2 , (b) —NHC(═NH)NH 2 and (c) hydrogen;

or a pharmaceutically acceptable salt or tautomer thereof.

6. The compound according to claim 5 , wherein C—B-A- is selected from the group consisting of:

or a pharmaceutically acceptable salt or tautomer thereof.

7. The compound according to claim 3 , wherein G is selected from

(a) a 3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(b) a 3-14 member saturated, unsaturated, or aromatic carbocycle, and

(c) a single bond;

wherein (a) or (b) is optionally substituted with one or more R 5 groups,

or a pharmaceutically acceptable salt or tautomer thereof.

8. The compound according to claim 4 , wherein R 5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NH 2 , (k) —OR 6 , (l) —NHC(═NH)NH 2 , (m) —C 1-8 alkyl, (n) —C 1-8 alkenyl, (o) —C 1-8 alkynyl, (p) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r) -haloalkyl, (s) —SR 6 , (t) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u) -3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R 5 groups are taken together to form a carbocycle, or a pharmaceutically acceptable salt or tautomer thereof.

9. The compound according to claim 4 , wherein R 6 is selected from (a) hydrogen, (b) —C 1-8 alkyl or alternatively two R 6 groups are taken together to form a carbocycle, (c) -haloalkyl, (d) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e) -3-14 member saturated, unsaturated, or aromatic carbocycle, or a pharmaceutically acceptable salt or tautomer thereof.

10. The compound according to claim 7 , wherein G is selected from azepanyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, pyridinyl, cyclohexenyl, cyclohexadienyl, dihydropyridyl, furanyl, tetrahydrofuranyl, tetrahydropyridyl, azetidinyl, pyrrolidinyl, piperidinyl, piperidenyl, and a single bond; or a pharmaceutically acceptable salt or tautomer thereof.

11. The compound according to claim 10 , wherein -G-H-J is selected from: hydrogen,

or a pharmaceutically acceptable salt or tautomer thereof.

12. The compound according to claim 11 wherein each -G-H-J is selected from:

wherein R 5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) —CF 3 , (g) —CN, (h) —N 3 (i) —NO 2 , (j) —NH 2 , (k) —OR 6 , (l) —NHC(═NH)NH 2 , (m) —C 1-8 alkyl, (n) —C 1-8 alkenyl, (o) —C 1-8 alkynyl, (p) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) —(C 1-8 alkyl)-(3-14 member saturated, unsaturated, or aromatic carbocycle), (r) -haloalkyl, (s) (t) -3-14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u) -3-14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R 5 groups are taken together to form a carbocycle,

or a pharmaceutically acceptable salt or tautomer thereof.

13. The compound according to claim 1 , selected from the group consisting of:

Comp.

No.

Structure

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

134

137

138

139

140

141

143

144

145

146

147

148

150

151

152

153

155

156

157

158

159

160

163

164

165

166

167

175

176

177

185

186

187

189

190

199

207

208

212

213

214

215

222

223

1305

or a pharmaceutically acceptable salt or tautomer thereof.

14. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt or tautomer thereof, and a pharmaceutically acceptable carrier.